Proposals for a scheme submitted for rapid revision are treated confidentially by NICE and all matters relating to the proposal for a Regulation (with the exception of the existence of the Scheme proposal) generally remain confidential, unless the review by the Evaluation Committee does not alter the guidance recommendations. In this case, NICE issues an ADF to lodge an appeal (see section 3.5.44). NICE publishes information during the ADF appeal phase in order to understand the proposed scheme and its impact on clinical efficacy, cost-effectiveness and recommendations. In an ever-changing market access environment, the industry has a wider choice of options. But does this further complicate the path to commercialization? Patient Access Scheme (PAS): price agreements offered by pharmaceutical companies to allow patients to access expensive medicines. Until then, the possibilities for improving the cost-effectiveness of a product controlled by the NICE-TA process were relatively simple; No or no passport. The introduction of Commercial Access Agreements (CAAs) and Market Access Agreements (MAAs) around 2016 offered industry additional options to propose more innovative mechanisms to obtain nice positive guidelines for technical assistance. These will be agreements submitted, verified and approved by NHS England, which can be considered as PASs by nice technology application committees. 4.6 NICE can only take into account proposals for patient access schemes, flexible price proposals and commercial access agreements after formal approval by England (see Figure 6).
. . .